Cargando…

Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature

Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have u...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynaert, Hendrik, Colle, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801667/
https://www.ncbi.nlm.nih.gov/pubmed/31569719
http://dx.doi.org/10.3390/ijms20194811
_version_ 1783460629846163456
author Reynaert, Hendrik
Colle, Isabelle
author_facet Reynaert, Hendrik
Colle, Isabelle
author_sort Reynaert, Hendrik
collection PubMed
description Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have underlying cirrhosis, which complicates or even precludes treatment. Therefore, efficacious treatments without major side effects are welcomed. Initial results of treatment of advanced hepatocellular carcinoma with somatostatin analogues were promising, but subsequent trials have resulted in conflicting outcomes. This might be explained by different patient populations, differences in dosage and type of treatment and differences in somatostatin receptor expression in the tumor or surrounding tissue. It has been shown that the expression of somatostatin receptors in the tumor might be of importance to select patients who could benefit from treatment with somatostatin analogues. Moreover, somatostatin receptor expression in hepatocellular carcinoma has been shown to correlate with recurrence, prognosis, and survival. In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact.
format Online
Article
Text
id pubmed-6801667
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68016672019-10-31 Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature Reynaert, Hendrik Colle, Isabelle Int J Mol Sci Review Hepatocellular carcinoma, one of the most dreaded complications of cirrhosis, is a frequent cancer with high mortality. Early primary liver cancer can be treated by surgery or ablation techniques, but advanced hepatocellular carcinoma remains a challenge for clinicians. Most of these patients have underlying cirrhosis, which complicates or even precludes treatment. Therefore, efficacious treatments without major side effects are welcomed. Initial results of treatment of advanced hepatocellular carcinoma with somatostatin analogues were promising, but subsequent trials have resulted in conflicting outcomes. This might be explained by different patient populations, differences in dosage and type of treatment and differences in somatostatin receptor expression in the tumor or surrounding tissue. It has been shown that the expression of somatostatin receptors in the tumor might be of importance to select patients who could benefit from treatment with somatostatin analogues. Moreover, somatostatin receptor expression in hepatocellular carcinoma has been shown to correlate with recurrence, prognosis, and survival. In this review, we will summarize the available data on treatment of primary liver cancer with somatostatin analogues and analyze the current knowledge of somatostatin receptor expression in hepatocellular carcinoma and its possible clinical impact. MDPI 2019-09-27 /pmc/articles/PMC6801667/ /pubmed/31569719 http://dx.doi.org/10.3390/ijms20194811 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reynaert, Hendrik
Colle, Isabelle
Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title_full Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title_fullStr Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title_full_unstemmed Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title_short Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature
title_sort treatment of advanced hepatocellular carcinoma with somatostatin analogues: a review of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801667/
https://www.ncbi.nlm.nih.gov/pubmed/31569719
http://dx.doi.org/10.3390/ijms20194811
work_keys_str_mv AT reynaerthendrik treatmentofadvancedhepatocellularcarcinomawithsomatostatinanaloguesareviewoftheliterature
AT colleisabelle treatmentofadvancedhepatocellularcarcinomawithsomatostatinanaloguesareviewoftheliterature